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Abstract
Despite the growing understanding of PDGF signaling, studies of PDGF function have encountered two major obstacles: the
functional redundancy of PDGFRa and PDGFRb in vitro and their distinct roles in vivo. Here we used wild-type mouse
embryonic fibroblasts (MEF), MEF null for either PDGFRa, b, or both to dissect PDGF-PDGFR signaling pathways. These four
PDGFR genetically defined cells provided us a platform to study the relative contributions of the pathways triggered by the
two PDGF receptors. They were treated with PDGF-BB and analyzed for differential gene expression, in vitro proliferation
and differential response to pharmacological effects. No genes were differentially expressed in the double null cells,
suggesting minimal receptor-independent signaling. Protean differentiation and proliferation pathways are commonly
regulated by PDGFRa, PDGFRb and PDGFRa/b while each receptor is also responsible for regulating unique signaling
pathways. Furthermore, some signaling is solely modulated through heterodimeric PDGFRa/b.
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Introduction
Platelet-derived growth factor (PDGF) is the principal mitogen
in serum for mesenchymal cells and consists of a family of A, B, C,
and D polypeptides which promote cell migration, proliferation,
and survival by binding to their cognate homo- or heterodimeric
tyrosine kinase receptors, PDGFRa and PDGFRb[1,2,3]. En-
hanced signaling of PDGF has been implicated in the pathogenesis
of atherosclerosis, balloon injury induced restenosis, pulmonary
fibrosis, angiogenesis, and tumorigenesis [4].
Tumor growth can be promoted by PDGF via autocrine
stimulation of malignant cells, by overexpression or overactivation
of PDGFRs, or by PDGF stimulation of angiogenesis within the
tumor. Constitutive activation of PDGFRa or PDGFRb is seen in
myeloid malignancies as a consequence of fusion to diverse partner
genes, and activating mutations of PDGFRa are seen in
gastrointestinal tumors (GISTs). Active PDGFRa was also found
in non-small cell lung cancer[5]. Autocrine signaling as a
consequence of PDGF overexpression has been implicated in the
pathogenesis of dermatofibrosarcoma protruberans (DFSP) and
overexpression of PDGFRs and/or their ligands has been
described in many other solid tumors such as medulloblastomas
and malignant gliomas [6,7]. Therefore, PDGFRs have increas-
ingly become targets for anticancer therapeutics and antirestenosis
agents. Two main approaches have been taken toward the
inhibition of cancer growth when PDGF-PDGFR signaling is
activated: (a) direct targeting of tumor cells in which PDGF
signaling is activated, and (b) indirect inhibition of tumors by
targeting pericytes to block tumor angiogenesis independently of
PDGF activity. A PDGFR inhibitor, imatinib mesylate (Gleevec,
STI-571), has benefited patients with myeloid malignancies, GIST
and DFSP [8]. PI3K-AKT-mTOR cascade is one of the most
frequently deregulated pathway in cancers [9,10,11]. Recently we
have found that the PDGF receptors are critical for the PI3K/
AKT activation and negatively regulated by mTOR. This
negative feedback mechanism is important in the prevention of
aberrant cell proliferation/growth such as tumor formation and
has significant implication in the targeted inhibition of this
pathway for cancer treatment [12,13].
Despite the growing understanding of PDGF signaling, studies
of PDGF function have met two obstacles. First, PDGF stimulates
a very similar set of cellular responses and signaling events in
cultured cells expressing only PDGFRa or PDGFRb. Because of
their functional redundancy or compensation of the receptors with
respect to one another in vitro, the signaling events of PDGFRa or
PDGFRb cannot be readily analyzed and differentiated. Second,
in contrast to in vitro studies, PDGFRa and PDGFRb have
dramatically different roles in vivo. The mechanism of PDGFR
signaling during development is poorly understood because
deletion of either the PDGFRa or PDGFRb leads to early
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deficient in smooth muscle cells, particularly vascular smooth
muscle cells and pericytes, a large number of different mesenchy-
mal cells are affected in PDGFRa null embryos. The distinct
phenotypes of mice lacking either PDGFRa or PDGFRb suggest
that PDGFRs might have unique effectors and/or distinct spatial
and temporal expression pattern in vivo.
In this study we employed a panel of PDGFR genetically
defined cell lines as a platform that allows us to examine the
relative contributions of the two receptors to PDGF signaling. We
studied the gene expression profile and in vitro proliferation assays
of the four different genotypes of PDGF receptors: PDGFRa/b
double null, PDGFRb null, PDGFRa null or WT PDGFRa/b in
MEF cells. These profiles were then dissected analytically using
gene set oriented techniques and complementary data from
protein interaction databases. The genes identified in this analysis
were then investigated further via protein expression and
phosphorylation status analyses. Their functional relevance was
then studied.
Results
Characterization of PDGFR knockout cell lines
To investigate the role of PDGFRs in cellular proliferation in
response to PDGF stimulation, cells were grown in serum free
Cellgro COMPLETE
TM medium with or without PDGF. In the
absence of PDGF, the proliferation rates of all four PDGFR
genetically defined cell lines were found to be similar. However,
with the addition of PDGF-BB, PDGFRb null, PDGFRa null and
WT cells proliferate faster than the PDGFRa/b double null cells
(Figure 1A). In addition, we examined the role that each of the
PDGF receptors plays in promoting cell migration and invasion.
PDGFRa, PDGFRb and heterodimeric PDGFRa/b were dem-
onstrated to promote cell migration and also PDGFRb and
heterodimeric PDGFRa/b to enhance cell invasion (Figure 1B).
Furthermore, PDGF-PDGFR is a known trigger of at least two
pathways: the PI3K-AKT and MAPK pathways. To investigate
the ability of PDGF to stimulate these pathways in our system, we
treated cells with 50 ng/ml of PDGF-BB for various durations.
For 10 min post treatment, ERK protein in PDGFRb null,
PDGFRa null, and WT cell lines was extensively phosphorylated,
compared with the no treatment by PDGF-BB (Figure 1C). The
phosphorylation of AKT protein at various time points showed a
similar pattern to ERK phosphorylation and decreased after 24 h.
However, in the PDGFRa and PDGFRb double null cell line,
neither ERK nor AKT phosphorylation was increased after the
PDGF-BB stimulation.
Differentially Expressed Genes
To study the role of PDGFRs in PDGF mediated transcription,
cells were treated with or without PDGF-BB for 1 h. Analysis of
the microarray expression data yielded lists of transcripts that were
differentially expressed (responded to PDGF-BB) with high
statistical confidence in each of the four cell lines. As described
in the Experimental Procedures section, the Significance Analysis
of Microarrays (SAM) [14] method was used to identify
differentially expressed genes with a false discovery rate ,0.05.
By comparing these lists, we identified genes that responded to
PDGF-BB treatment uniquely in each cell line, and also genes that
responded to treatment in multiple cell lines. For example, Figure 2
shows a heatmap describing the transcriptional activity of the
genes that were identified in common among the PDGFRb null,
PDGFRa null and WT cell lines (genes such as Txnip, Fos, Egr1,
Egr2, Fra-1 (FOSL1), ATF-3, and NR4A1 were all identified as
differentially expressed in this particular comparison). The
complete list of genes affected by treatment in each cell line can
be found in the Supplemental Material (see Table S1 Diff-Genes-
PDGF-BB-Treatment.xls).
Gene Ontology (GO) terms associated with differentially
expressed genes
In order to identify functional similarities among the genes that
were differentially expressed in one or more of the treatment
conditions, we identified GO terms that were statistically
overrepresented in each list of genes as described in Materials
and Methods. Figure 3 shows the GO Molecular Function terms
that were enriched for each cell line. Lists enumerating all of the
enriched GO terms for each cell line can be found in the
Supplemental Material (see Table S2 GO-Enrichment-PDGF-BB-
Treatment.xls). The GO terms characterizing the WT alone (in
green) cover transcriptional control and apoptotic programs.
Examination of which genes are responsible for this enrichment
reveals central ‘‘actors’’ in proliferation, differentiation and
apoptosis such as: HES1, BHLHB2, JunB, FOSL1, SRF, SKIL,
EGR1, NAB2, FOSB, NR4A1, CCL2 and SERPINE1. The
PDGFRa null cell line but not the PDGFRb null or WT showed
differential expression of GDP signaling genes (i.e. required the
PDGFRb isoform, but may be repressed by activity of the
PDGFRa isoform). Conversely, the differentially expressed GO
sets particular to the PDGFRb null and WT cell lines (i.e.
requiring the PDGFRa isoform) characterize ketosteroid metab-
olism (colored magenta). Red nodes represent those sets that were
found to be differentially expressed in all but the double (a/b) null
cell lines, and include the MAP kinase pathway, prostaglandin
signaling pathways and several other signaling pathways.
Gene set (pathway) analysis
In addition to the differential expression analysis, we used
sigPathway [15] to identify functional groups of genes (e.g.,
pathways) that exhibited significantly different behavior between
the various conditions. As with the differential expression analysis,
we first identified gene sets by comparing the treatment to the non-
treatment condition for each of the cell lines. We then compared
the pathways identified for each cell line to one another in order to
determine which functionality could be attributed most strongly to
stimulation of each combination of receptors. The double null
data was not included in this analysis because our differential
expression analysis indicated that there was no significant change
in transcriptional activity that resulted from treatment of the
double null cell line. Table 1 lists the gene sets identified as
responding to treatment in the various cell lines.
Several pathways were ranked highly for all three cell lines in
this analysis, indicating that these pathways were activated by all of
the receptors after PDGF-BB stimulation, including cAMP/Ca
signaling and G-protein coupled receptor signaling. In addition,
many pathways were highly-ranked in only a strict subset of the
cell lines. For example, the IL6 and NFkB signaling pathways
were both stimulated in the WT cell line; C21-steroid hormone
biosynthesis was stimulated in the PDGFRb null cell line;
angiogenesis and epidermal growth factor receptor signaling
pathway were both stimulated in the PDGFRa null cell line.
All PDGF signaling is PDGFR-dependent
None of the mRNA targets probed by the microarrays exceeded
our differential expression threshold in the double null cell line,
indicating that transcriptional response to PDGF-BB ligand is
mediated entirely through activation of one or both of the PDGF
PDGF-PDGFR Signaling
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the mRNA expression fold-change vectors for each cell line
(Table 2). This analysis revealed that transcriptional responses to
PDGF-BB in the PDGFRa null and PDGFRb null cells are more
similar to the expression response of the WT cells than they are to
one another, or the double null cells. The double null cell line’s
response to PDGF-BB was essentially uncorrelated with that of the
other three cell lines.
PDGF-independent PDGFR function
In order to study the function of the two receptors independent
of their activation state, we sought genes whose transcription levels
changed between the PDGFRa null, PDGFRb null and WT
samples when compared to the untreated double null samples. We
then repeated this analysis using the treated samples (i.e., which
genes were differentially expressed in the treated PDGFRa null/
PDGFRb null/WT vs. the treated double null cells). We identified
those genes whose expression changes were conserved between the
untreated and PDGF-BB treated cells. We suggest that these genes
are regulated by the presence or absence of a particular receptor,
rather than by activation of a receptor through growth factor
ligation. Please see Supplemental Material (see Table S3 PDGF-
Independent-Gene-Lists.xls) for complete lists of these transcripts.
Interactome of dissected pathways of PDGFR reveals
central processes
We constructed a protein-interaction network based on the
annotations present in the HPRD database. We included all
interactions where both proteins were the products of genes that
were differentially expressed in at least one cell line. Figure 4
shows this network, with each gene labeled by color to indicate the
cell lines where it was differentially expressed. Interpretation of this
network must be cautious; at the very least because there is
significant bias of protein-interaction databases towards those
pathways that are better characterized. Nonetheless, we identified
significantly enriched pathways (i.e. hypergeometric p value,
corrected for multiple hypothesis testing, ,0.05) among the
various combinations of receptor systems. For example, A2B
adenosine receptor related processes were identified among the
dark blue nodes (see Table S4 GO-Enrichment-for-PPI-Figure.xls
in Supplementary Materials for all pathways).
Protein level validation of microarray results through
selected protein level assays of the PDGFRa and PDGFRb
systems
Immunoblotting was used to examine the effect of PDGF-BB
treatment at the protein-level for several of the genes identified by
the microarray analysis. As per mRNA expression data, Txnip
(thioredoxin-interacting protein) was identified as one of the most
significantly down-regulated mRNA transcripts. As shown in
Figures 2 and 5, protein expression of Txnip is mainly suppressed
by PDGFRa, since Txnip is reduced in the presence of PDGFRa
and diminished with the activation of PDGFRa by PDGF
stimulation. PDGFRb may have some effects during longer
treatment. To confirm this result, we also performed Western
blotting with a different ligand (PDGF-AA, 50 ng/ml) to assess the
level of Txnip protein expression. The results showed that Txnip
was down-regulated in the cell lines containing PDGFRa and
heterodimeric PDGFRa/b (Figure 5A). In the regular medium ,
Txnip was also down regulated in the PDGFRa (PDGFRb null
cell line) and WT cell line (Figure 5B). PDGF is one of main
growth factors in FBS and thus is sufficient to suppress Txnip in
PDGFRa and WT cell line. Txnip gene expression was further
validated by real time-PCR (Figure 5c).
Protein expression of Nurr1 (Nr4a2) and Nur77 (Nr4a1) are
altered only in the PDGFR WT cell line post 10 min stimulation
of PDGF-BB. This is consistent with the microarray data, where
production of mRNA for Nurr1 was induced only in the WT cell
line, and production of mRNA for Nur77 was induced most
drastically in the WT cell line, and less so in the PDGFRb null and
PDGFRa null cell lines (Figure 2). EGR1 is an early response gene
and its protein expression is up-regulated in the PDGFRb null,
PDGFRa null and WT cell lines, but not in the PDGFR double
null cell line at 1 h treatment with PDGF-BB. This is also
consistent with the microarray data. ATF-3 is up-regulated in the
PDGFRb null, PDGFRa null and WT cell lines, but not in the
PDGFR double null cell line, even at 24 h treatment with PDGF-
BB. In the PDGFRa null cell line, protein levels of ATF-3
gradually increase at all time points. This is somewhat different
from the PDGFRb null and WT cell lines where ATF-3 protein
levels are increased at early time points and gradually decrease
thereafter. This indicates that ATF-3 is regulated differently by
PDGFRa, PDGFRb and heterodimeric PDGFRa/b. These
results again agree with the microarray analysis (Figure 2).
Pathway validation by protein level
As described above, we employed the sigPathway method [15]
to identify functional groups of genes that exhibited significantly
different behavior between the various conditions. We used
Western blotting to validate components of one of the pathways,
IL6, identified as up-regulated significantly (p,0.05) in the WT
cell line in response to PDGF stimulation (Figure 6 A and B). In
this IL6 pathway, the genes Fos, Cebpb (NF-IL6), Jun and IL6
were significantly upregulated (p,0.05). As shown in Figure 6C, a
few key component genes such as Cebpb (NF-IL6), Fos and Jun in
the IL6 pathway were demonstrated as up-regulated by Western
blotting. Fos and Jun were up-regulated with PDGF-BB treatment
for 1 h while Cebpb (NF-IL6) was little changed. In the absence of
PDGF-BB treatment, Jun expression was slightly higher in the
PDGFRb null and WT cell lines than in the others.
Pharmacological dissection of the PDGF-PDGFR signaling
pathways with STI-571
STI-571 (imatinib mesylae, Gleevec, Novartis, Basel, Switzer-
land) inhibits phosphorylation of both PDGFRa and PDGFRb
and their downstream targets ERK and AKT [16,17]. In this
Figure 1. Characterization of four PDGFR genetically defined MEF cell lines. A: PDGF-BB promotes cell proliferation through PDGFR. 1610
5
cells were plated at Day 0 and then counted each day for next consecutive three days. Dot lines: cells grown in FBS-free Cellgro Complete medium.
Solid lines: cells grown in FBS-free Cellgro Complete medium with PDGF-BB (50 ng/ml). B: PDGFR is required for PDGF mediated cell migration and
invasion. Cell migration and invasion were measured by a 24-well chamber-based assay. 2.5610
4 cells were seeded in the upper chamber in FBS free
Cellgro Complete medium. The lower chamber was filled with Cellgro Complete medium with no FBS, 10% FBS or PDGF-BB (50 ng/ml). After 24 h,
the cells in the lower chamber were labeled with Calcein AM and detached. The detached labeled cells were then measured for fluorescence. Upper
panel: Migration assay. Lower panel: Invasion assay. C: PDGF-mediated PI3K and MAP kinase signalings are absent in PDGFRa and PDGFRb double
deficient cell lines. Four cell lines were treated with PDGF-BB (50 ng/ml) for 10 min, 1 hour (h), 4 h, 8 h and 24 h. The harvested lysates were
immunoblotted for PDGFRa, PDGFRb, p-ERK (Tyr 204), ERK, p-AKT (Ser473), and AKT. Data shown is one of the representative experiments.
doi:10.1371/journal.pone.0003794.g001
PDGF-PDGFR Signaling
PLoS ONE | www.plosone.org 4 November 2008 | Volume 3 | Issue 11 | e3794Figure 2. Representative PDGFR dependent differential gene expression in response to PDGF treatment. Upper panel: triplicate sets of
each cell line were treated with or without PDGF-BB for 1 h. mRNA expression profiles for the probe sets identified as differentially expressed in the
treatment group for all of the cell lines, except for double knockout. Expression levels of the probe sets interrogating the genes that were commonly
differentially expressed in the PDGFRb2/2 (beta null), PDGFRa2/2 (alpha null), and WT (PDGFRa+/+ PDGFRb+/+) cell lines are shown in the
heatmap. Each column represents a sample, each row a gene. Column labels indicate the cell line and treatment condition (T for samples treated with
PDGF-BB, U for untreated samples) for each sample. Each probe set’s expression has been independently normalized across the experiments. Bright
green shading indicates an expression level below the gene-wise mean, bright red indicates an expression level above the mean, while darker shades
indicate expression levels closer to the mean intensity. Lower panel: four cell lines were treated with PDGF-BB (50 ng/ml) for various times and their
lysates were immunoblotted for ATF-3, Txnip, Fra-1, Nurr1, Nur77, TF, and EGR1 (PDGF treatment does not influence the total Erk, therefore Erk was
regarded as a spotting control in this system, the same for the following experiments in the MEF cell lines with genetically defined PDGFRs) to
validate findings from the mRNA expression analysis (upper panel). Expression levels of probe sets interrogating the genes for these proteins are
shown in the heatmap above the western blot figure.
doi:10.1371/journal.pone.0003794.g002
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PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3794Table 1. Pathways identified in each of the PDGFR-defined cell lines
Cell Lines Source Gene Set
Wild Type Only GO:0030182 neuron differentiation
GO:0042417 dopamine metabolism
BioCarta Cadmium induces DNA synthesis and proliferation in macrophages
BioCarta IL 6 signaling pathway
GO:0001942 hair follicle development
BioCarta NFAT and Hypertrophy of the heart (Transcription in the broken heart)
GO:0042133 neurotransmitter metabolism
GO:0051239 regulation of organismal physiological process
GO:0008083 growth factor activity
mousepaths NFkB Signaling Pathway
GO:0030282 bone mineralization
GO:0045664 regulation of neuron differentiation
GO:0030574 collagen catabolism
GO:0007566 embryo implantation
GO:0009888 histogenesis
GO:0030522 intracellular receptor-mediated signaling pathway
GO:0030518 steroid hormone receptor signaling pathway
GO:0045638 negative regulation of myeloid cell differentiation
GO:0043154 negative regulation of caspase activation
GO:0001719 inhibition of caspase activation
GO:0001502 cartilage condensation
GO:0007565 pregnancy
GO:0006309 DNA fragmentation during apoptosis
GO:0006921 disassembly of cell structures during apoptosis
GO:0030262 apoptotic nuclear changes
Beta Null Only KEGG Synthesis_and_degradation_of_ketone_bodies
BioCarta SREBP control of lipid synthesis
GO:0008207 C21-steroid hormone metabolism
GO:0046912 transferase activity, transferring acyl groups, acyl groups converted into alkyl on
transfer
GO:0016229 steroid dehydrogenase activity
GO:0003918 DNA topoisomerase (ATP-hydrolyzing) activity
GO:0000123 histone acetyltransferase complex
GO:0000777 condensed chromosome kinetochore
GO:0006700 C21-steroid hormone biosynthesis
BioCarta Granzyme A mediated Apoptosis Pathway
GO:0005694 chromosome
GO:0050728 negative regulation of inflammatory response
GO:0000278 mitotic cell cycle
GO:0030529 ribonucleoprotein complex
GO:0006281 DNA repair
GO:0009613 response to pest, pathogen or parasite
GO:0050877 neurophysiological process
GO:0043207 response to external biotic stimulus
BioCarta The information-processing pathway at the IFN-beta enhancer
BioCarta Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases
GO:0008217 regulation of blood pressure
KEGG Cytokine-cytokine_receptor_interaction
GO:0006974 response to DNA damage stimulus
GO:0001584 rhodopsin-like receptor activity
BioCarta Transcription Regulation by Methyltransferase of CARM1
BioCarta Mechanism of Acetaminophen Activity and Toxicity
PDGF-PDGFR Signaling
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GO:0016070 RNA metabolism
BioCarta Platelet Amyloid Precursor Protein Pathway
GO:0004930 G-protein coupled receptor activity
GO:0015268 alpha-type channel activity
GO:0015267 channel or pore class transporter activity
GO:0004709 MAP kinase kinase kinase activity
GO:0007186 G-protein coupled receptor protein signaling pathway
Alpha Knockout Only mousepaths Th1-Th2-Th3
GO:0006692 prostanoid metabolism
GO:0006693 prostaglandin metabolism
BioCarta Eicosanoid Metabolism
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0001525 angiogenesis
GO:0048514 blood vessel morphogenesis
GO:0001508 regulation of action potential
GO:0045670 regulation of osteoclast differentiation
GO:0046456 icosanoid biosynthesis
GO:0006690 icosanoid metabolism
GO:0030316 osteoclast differentiation
KEGG Prostaglandin_and_leukotriene_metabolism
GO:0030224 monocyte differentiation
GO:0007205 protein kinase C activation
Beta Knockout and Wild Type GO:0016126 sterol biosynthesis
GO:0006695 cholesterol biosynthesis
Alpha Knockout and Wild Type BioCarta Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells
mousepaths Ca _ NFAT Signaling Pathways
mousepaths Breast Cancer _ Estrogen Receptor Signaling
mousepaths Signal Transduction in Cancer
mousepaths Cardiovascular Disease
mousepaths Signal Transduction PathwayFinder
mousepaths Nitric Oxide
mousepaths Tumor Metastasis
mousepaths Autoimmune and Inflammatory Response
mousepaths Angiogenesis
mousepaths Endothelial Cell Biology
GO:0008015 circulation
GO:0008016 regulation of heart contraction rate
GO:0042552 myelination
GO:0042553 cellular nerve ensheathment
GO:0007272 ionic insulation of neurons by glial cells
GO:0008366 nerve ensheathment
Alpha Knockout and Beta Knockout GO:0045765 regulation of angiogenesis
GO:0046457 prostanoid biosynthesis
GO:0001516 prostaglandin biosynthesis
GO:0016525 negative regulation of angiogenesis
GO:0006955 immune response
GO:0006952 defense response
GO:0000279 M phase
Table 1. cont
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PDGF-PDGFR pathway by inhibiting the different isoforms of the
receptor. The dosage 5 mM of STI-571 was selected to inhibit
PDGFRa and PDGFRb efficiently [18].
As in Figure 6D, p-AKT was inhibited in PDGFRb null,
PDGFRa null and WT cell lines, while p-ERK was mainly
inhibited in PDGFRa containing cells upon the STI-571
treatment. C-Fos was moderately inhibited in PDGFRb null and
PDGFRa null while its expression was strongly inhibited in WT
cells by the drug. ATF3 was not inhibited in PDGFRb null,
PDGFRa null and WT cell lines by STI-571 alone, but was
inhibited in PDGFRb null, PDGFRa null and WT cell lines by
STI-571 in the presence of both PDGF-BB. Fra-1 (FOSL1)
expression did not change significantly in the PDGFRb null,
PDGFRa null and WT cell lines by STI-571 while its expression
was increased in the PDGFRb null, PDGFRa null and WT cell
lines in the presence of both PDGF-BB and STI-571. It is notable
that PDGF-BB stimulation could not reverse the STI-571
inhibition effect on some genes’ expression even though
PDGFR-BB moderately increased the expression of C-Fos and
Fra-1 as compared to STI-571 inhibition alone.
Discussion
In this study, we have demonstrated a first ‘‘cut’’ dissection
exercise of the PDGFR signaling systems by using the gene
expression profile of the four states of PDGF receptors in the
PDGFR genetically defined MEF cells and complemented these
results with protein-level validation and pharmacological response
studies.
We have confirmed some of the genes previously implicated in
the PDGF-PDGFR pathway, such as FOS, NR4A1, ZFP36,
EGR2, NR4A2, EGR3, FOSB, ATF3, JUN, IER3, ADRB2,
DUSP6, MCL1, RGS2, MYC, F3, BHLHB2, GEM, EGR1, LIF
and CEBPB [19,20]. We also identified the involvement of Axud1,
MCl1, Tiparp and Txnip in the PDGF-PDGFR system as
previously identified by Chen et al. [21] using a microarray-
coupled gene-trap mutagenesis method. Furthermore we have
been able to add more genes to the list such as PTGS2, ERRFI1,
JUNB, FOSL1, ERRFI1, EREG, HBEGF, CH25H, HOMER1,
PHLDA1, FOS, KLF10, FOSB, SERPINE1, DUSP5, EREG,
GEM, HOMER1, HBEGF, TRIB1, CCL2, NFIL3, LBH, IER2,
MMP13, GS2, AREG, RSBN1, LIF, TNFRSF11B, CXCL1,
NFKBIZ, DUSP4, CCL7, RSBN1, RGS2, IER3, ARL5B, BTG2,
ADAMTS1, BTG2, IER5, HES1, RGS2, AXUD1, MMP3,
PTGER4 etc.
PDGFRa and PDGFRb activate many overlapping signaling
pathways. All of the receptors activate the same pathways such as
cAMP/Ca+ signaling and G-protein coupled receptor signaling
after the PDGF-BB stimulation. However, some signaling
pathways are exclusively or predominantly activated by one
receptor but not the other. Here, we demonstrated that 33 gene
sets were activated by PDGFRa only and 15 genes sets by
PDGFRb only. 25 genes sets were specifically activated by
PDGFRa/b heterodimers. For example, PDGFRa/b activated
components of the NFkB and IL6 signaling pathways, PDGFRa
activated C21-steroid hormone biosynthesis; and PDGFRb
activated the angiogenesis and epidermal growth factor receptor
signaling pathways. Previous investigations of the pathways
regulated by PDGFRs were done one pathway at a time[22];
here we used a bioinformatics approach to comprehensively
analyze ,multiple pathways. Nonetheless, the earlier study
suggested the Ca++ fluxes pathway is regulated by both PDGFRa
and PDGFRb [22] and angiogenesis is only transduced by
PDGFRb [22,23]. Our current study is agreement with the
previous study (Table 1).
Txnip was identified here to be highly suppressed by PDGFRa.
It is identical to VDUP1 (Vitamin D3 up-regulated protein 1)
[24,25]. Txnip/VDUP1 is a known tumor suppressor, cell cycle
inhibitor and a factor contributing to P27kip1 stability
[26,27,28,29]. Recently, PDGF has been shown to suppress
VDUP1 at the mRNA level [30]. We have confirmed that Txnip is
down-regulated by PDGF at both the mRNA level and protein
level. Furthermore, we identified PDGFRa as the suppressor of
Txnip in response to PDGF signaling (Figure 2 and Figure 5).
Table 2. Pearson correlation between the vectors of fold
change values (all probe sets, treated v.s. untreated
conditions) for the four cell lines
Pearson
Correlation Double null Alpha null Beta null WT
Double null 1.000 0.0712 20.034 0.041
Alpha null 0.071 1.000 0.719 0.780
Beta null 20.035 0.719 1.000 0.770
WT 0.0417 0.780 0.770 1.000
Notice that the responses of both the PDGFRb knock out cell line and PDGFRa
null cell line to PDGF-BB treatment are more similar to that of the WT cell line
than any of the others. The response of the double null cell line is essentially
uncorrelated with the response of the other three cell lines.
doi:10.1371/journal.pone.0003794.t002
Cell Lines Source Gene Set
GO:0007067 mitosis
GO:0000087 M phase of mitotic cell cycle
GO:0003735 structural constituent of ribosome
GO:0005840 ribosome
KEGG Ribosome
Alpha Knockout, Beta Knockout
and Wild Type
mousepaths cAMP _ Ca Signaling PathwayFinder
mousepaths G-Protein Coupled Receptors Signaling PathwayFinder
doi:10.1371/journal.pone.0003794.t001
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PLoS ONE | www.plosone.org 9 November 2008 | Volume 3 | Issue 11 | e3794NR4A1/Nur77 and NR4A2/Nurr1 genes are two members of
nuclear hormone receptor family (including Nur77, Nurr1 and
Nor-1 or NR4A1-3) [31]. It has been demonstrated that the
constitutive expression of Nur77 may induce apoptosis while
transient expression does not [31]. With addition of PDGF, Nurr1
and Nur77 protein levels are transiently up-regulated in 10 min,
which may protect cells against apoptosis. This occurs only in the
presence of PDGFRa with PDGF stimulation. It also has been
Figure 4. Protein interaction map for differentially expressed genes. The HPRD database was searched for records that reference genes that
were differentially expressed in one or more of the PDGFR defined cell lines after stimulation with PDGF-BB ligand. The network shown here
represents all of the records in HPRD where both interacting proteins were among the differentially expressed genes. Red nodes represent genes that
were differentially expressed in the alpha null, beta null and WT cell lines. Cyan nodes represent genes that were differentially expressed in the alpha
null and WT cell lines, but not in the beta null. Dark blue nodes represent genes that were differentially expressed only in the alpha nullcell line. Green
nodes represent genes that were differentially expressed only in the WT (heterodimer) cell line.
doi:10.1371/journal.pone.0003794.g004
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context of TNF alpha mediated signaling [31]. The mechanism for
Nur77 as a survival effecter protein needs to be further
investigated. A very recent study showed that the third member
in the nuclear hormone receptor family NR4A orphan nuclear
receptor NOR1 is induced by PDGF and mediates vascular
smooth muscle cell proliferation [32].This finding suggests that the
nuclear hormone receptor family are therapeutic targets for some
diseases in which PDGFRs are overexpressed.
These results are illustrative of the combinatorial richness of
PDGF receptor/ligand-mediated signaling. Our results begin to
reveal the downstream interplay of the signaling events brought
about by the activation of each of the two receptors, indicating the
biological effect of receptor/ligand specificity. Furthermore, in this
study, we have demonstrated that transcriptional response to
PDGF-BB ligand is mediated entirely through activation of one or
both of its receptors and suggest that PDGF ligand, PDGF-BB in
this study, does not bind any other receptors.
Similar to the stimulation of PDGF, the responsiveness of
PDGF receptors to pharmacological inhibition is also complex.
While STI-571 inhibits AKT activation through either PDGFRa
or PDGFRb, it blocks ERK activation mainly through PDGFRa
Figure 5. Activation of PDGFRa suppresses Txnip expression. Txnip was downregulated in PDGFRb null (beta KO) and WT cell lines with
PDGF-BB and AA treatments (A) and (C) or with regular medium (10% FBS containing DMEM) (B). A: Immunoblotting for Txnip and ERK in four cell
lines treated with PDGF-BB (50 ng/ml) and PDGF-AA (50 ng/ml) for 10 min and 1 h. B: Immunoblotting for Txnip and ERK from the same cells grown
in regular medium. C: RNA was extracted from 4 cell lines (double KO, Beta KO, Alpha KO and WT) treated without or with PDGF-BB (50 ng/ml) for
1 h. Txnip gene expression was assessed by reverse transcription-quantitative PCR and normalized using GAPDH as the internal control. The result is
one representative of three independent experiments.
doi:10.1371/journal.pone.0003794.g005
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PLoS ONE | www.plosone.org 11 November 2008 | Volume 3 | Issue 11 | e3794Figure 6. PDGFR regulates IL6 pathway and the signaling pathways modulated by STI-571. A and B: Triplicate sets of each cell line were
treated with or without PDGF-BB (50 ng/ml) for 1 h. Expression levels of the genes in the IL6 pathway in the WT cell line are shown in panel A.
Expression values are summarized over multiple probe sets for each gene, and a standard Student’s T-test p-value indicates the strength of the
difference-of-the-means between the treatment groups. In panel B, the expression patterns (across all cell lines) of a few selected genes from the IL6
pathway are shown along with their respective Western blot results in panel C. In both heatmaps, bright green shading indicates an expression level
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PLoS ONE | www.plosone.org 12 November 2008 | Volume 3 | Issue 11 | e3794(Figure 6). Therefore, this PDGFR platform may help us to further
understand the molecular mechanism of therapeutic inhibition on
PDGF-PDGFR signaling and identify additional critical molecular
targets for the intervention of cancer and other diseases.
The studies presented here are prone to many well-known
limitations, such as the noisiness of expression microarrays, the
frequent lack of concordance of gene and protein expression, and
the post-translational signaling systems that are at most only faintly
echoed in gene expression levels. We have attempted to minimize
these limitations by employing rigorous statistical techniques,
focusing on pathways as much as on individual genes, using
protein interaction data to corroborate co-expression findings and
using selected protein measurements, including previously impli-
cated post-translational modifications.
In summary, we have taken advantage of the experimental
platform presented by PDGFR double null cells, PDGFRa,
PDGFRb and PDGFR WT cell lines (where dimers PDGFRa/a,
PDGFRb/b, PDGFRa/b co-exist) and used a bioinformatics
approach to dissect the gene sets/pathways that are controlled by
two PDGFR isoforms with PDGF-BB ligand stimulation. Our
study also provides a reproducible approach to the dissection of
the contributions of a heteromeric receptor signaling system.
While minimal PDGF receptor-independent signaling was found,
we identified the signals commonly regulated by PDGFRa,
PDGFRb and PDGFRa/b, specifically triggered by each of the
two PDGF receptors as well as the heterodimeric PDGFRa/b.
Materials and Methods
Cells and viruses
PDGFRa/b double null (double KO) (a2/2b2/2), PDGFR
beta null (PDGFRa/b double null cells infected with PDGFRa
expressing retro-viruses), and PDGFR alpha null (PDGFRa/b
double null cells infected with PDGFRb expressing retro-viruses)
MEFs were gifts from Dr. Andrius Kazlauskas (Schepens Eye
Research Institute) [33]. Wild-type PDGFRa and PDGFRb MEFs
[PDGFRa+/+ b+/+] were generated as follows. Human
PDGFRb cDNA was amplified from hPDGFRb in pEF6
(Invitrogen, Carlsbad, CA) with primers (all primer sequences
available upon request) using proof-reading Pfu polymerase
(Stratagene, La Jolla, CA). The PCR products were digested with
Not I and Cla I (NEB Biolab, Ipswich, MA) and inserted into a
retroviral vector pIRES-hygromycin [34]. The plasmids were
transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
into the retroviral packaging cell line PT67 (Clontech, Palo Alto,
CA). Filtered medium containing viruses carrying PDGFRb was
used to infect PDGFRa+/+ b2/2 MEF. Infected cells were then
selected with 100 mg/ml hygromycin B (Clontech, Palo Alto, CA).
All cells were cultured in DMEM with or without 10% FBS in 5%
CO2 at 37uC.
DNA microarray hybridization
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
Valencia, CA) from cells that were treated or untreated with or
without 50 ng/ml PDGF-BB for 1 h. Five mg RNA of each sample
was used for double-stranded cDNA synthesis. In vitro transcription
was carried out using the Enzo BioArray High Yield RNA
Transcript Labeling Kit (Enzo, New York, NY). The labeled
cRNA target (20 mg each) was then fragmented into 35–200 base
pair fragments and hybridized to each Affymetrix GeneChipH
Mouse Genome 430 2.0 array according to Affymetrix Eukaryotic
Target Hybridization Protocol. Following a 16-h incubation the
microarrays were washed and scanned using the EukGE-WS2v4
fluidics protocol.
Differential expression analysis
Microarray data were normalized, background corrected and
summarized using the robust multi-array average (RMA2) method
[35]. We identified individual genes that exhibited statistically
significant differential expression as a result of PDGF treatment in
each null experiment (i.e., genes induced or repressed in the a2/
2 b2/2, a+/+ b2/2, a2/2b+/+, a+/+ b+/+ cells when
treated with PDGF-BB) using SAM method [14]. In each
comparison we selected a value for SAM’s D parameter to specify
a median false discovery rate less than 0.05, and we consider the
genes reported at this threshold to be differentially expressed
between the treatment and non-treatment conditions.
Gene set analysis
To identify functional groups of genes from each cell line with
RNA expression profiles that were affected by PDGF-BB
treatment, we used Tian et al’s [15] sigPathway method Gene
set annotations were assembled from Gene Ontology [36], KEGG
[37], BioCarta (biocarta.com), BioCyc [38] and custom data. This
method identifies significantly enriched gene sets by testing two
related null hypotheses: 1) The pattern of expression for the genes
in a particular gene set is the same as all the other genes, and 2) the
gene set does not contain genes with expression profiles that are
correlated with treatment. We picked out gene sets that were
distinguished by both statistics by ranking the sets by the sum of
the ranks of their two statistics. All of the gene sets presented here
had a false discovery rate below 0.05 for at least one statistic.
We identified statistically over-represented Gene Ontology
(GO) terms for the lists of differentially expressed genes by
computing a hypergeometric p-value for each GO annotation
associated with a given gene list. The resulting p-values were
corrected for multiple hypothesis testing using the FRD method
[39]. An FDR below 0.05 was regarded as indicating significant
over-representation.
Comparison of genes lists
Once lists of genes and pathways whose mRNA expression
responded to PDGF-BB treatment were assembled by the above
methods, we compared the lists to see which genes had responded
to treatment uniquely in one of the nulls or wild type, or common
to two or more of the null and wild type conditions.
Correlation analysis
In order to evaluate how similar each of the four cell lines’
transcriptional responses to PDGF-BB ligand stimulation were to
one another, Pearson correlation coefficients were computed
between all pairs of cell lines. The SAM software package for R
was used to compute fold change values (PDGF-BB treated
below the gene-wise mean, bright red indicates an expression level above the mean, while darker shades indicate expression levels closer to the
mean intensity. The mean and standard deviation for each (log-reduced) gene are shown to the right of each gene name. C: Four cell lines were
treated with PDGF-BB (50 ng/ml) for 10 min, 1 h. Cell lysates were immunoblotted for Jun, Cebpb, Fos and ERK (lower panel). D: Four cell lines were
pretreated with STI-571 (5 mM) for 90 minutes and then stimulated with PDGF-BB (50 ng/ml) for 1 h. The harvested lysates were immunoblotted for
PDGFRa, PDGFRb, AKT, p-AKT (Ser473), p-ERK (Tyr 204), ERK, EGR1, c-Jun, c-Fos, ATF-3, Fra-1, and b-actin (b-actin as internal control).
doi:10.1371/journal.pone.0003794.g006
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present in the normalized microarray data, for each cell line.
Thus, four vectors of fold change estimates were obtained (one for
double null, one for alpha null, one beta null and one for wild type)
representing each cell line’s response to ligand stimulation.
Pearson correlations between each pair of these vectors were
computed using R.
Western blot analysis
The cells were starved for two days, then left unstimulated, or
simulated with 50 ng/ml PDGF-BB (Sigma-Aldrich, Saint Louis,
MO) in six well plates in serum-free medium for specific time
points. Cell lysates were prepared and proteins were separated by
electrophoresis. The electroblotted nitrocellulose membranes were
probed with antibodies.
Antibodies were obtained from: PDGFRa (C-20), ERK (K-23),
p-ERK (E-4), Fra-1 (R-20), Nurr1 (M-196), Nur77 (M-210),TF (I-
20), Egr3 (C-24), ATF-3 (C-19), c-Fos (4), Cebpb (H-7) (Santa
Cruz Biotech, CA); PDGFRb (Upstate, Temecula, CA); p-AKT
(Ser473), AKT, EGR1 and c-jun (Cell Signaling Technology,
Beverly, MA); Txnip (MBL International, Woburn, MA).
Secondary antibodies were anti-mouse IgG, anti-rabbit IgG and
anti-goat IgG HRP (Santa Cruz Biotech, CA).
Cell proliferation, migration and invasion assays
Cells were cultured in Cellgro COMPLETE
TM with L-
glutamine & phenol red (40-101-CV, Mediatech, Herndon, VA)
in the presence or absence of growth/proliferation factor. Cell
numbers were counted every day in triplicates using Trypan Blue
dye exclusion method for cell viability (Vi-Cell, Beckman Coulter,
Fullerton, CA). Migration and invasion assays were performed
using 24-well chamber-based plates (BD Biosciences, Bedford,
MA). FBS or PDGF-BB was used as chemo-attractants.
Reverse transcription-quantitative PCR
One mg of RNA from each sample was reverse transcribed using
iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA)
according to the instructions of the manufacturer. The original
cDNA reaction mixture was diluted to one-tenth of the reaction
volume. 2 ml of the diluted cDNA was used as the template in the
quantitative PCR reaction. Amplification was done using iQ
SYBR Green Supermix on an iCycler (Bio-Rad, Hercules, CA)
(primer sequences for Txnip and GAPGH available upon request).
Statistical analysis
Hypergeometric p-values were used to evaluate GO term
enrichment. The raw p-values were corrected for multiple
hypothesis testing using the FRD method [39] to compute q-
values. Any q-value below 0.05 was considered significant.
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